Novavax (NVAX) Capital Expenditures (2010 - 2026)

Novavax's Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 20.38% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $5.2 million, a 261.03% increase from a year earlier, with the FY2025 full-year figure at $5.6 million, up 423.05% from the prior year.
• Capital Expenditures slipped to $1.3 million in Q1 2026 per NVAX's latest filing, from $5.3 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $66.0 million in Q3 2022 and bottomed at -$62.1 million in Q4 2022.
• The 5-year median for Capital Expenditures is $985000.0 (2024), against an average of $1.2 million.
• Biggest YoY gain for Capital Expenditures was 1076.1% in 2025; the steepest drop was 223.55% in 2025.
• Year by year, Capital Expenditures stood at -$62.1 million in 2022, then surged by 40.37% to -$37.0 million in 2023, then jumped by 98.53% to -$544000.0 in 2024, then soared by 1076.1% to $5.3 million in 2025, then tumbled by 76.08% to $1.3 million in 2026.
• Per Business Quant, the three latest NVAX Capital Expenditures figures stand at $1.3 million (Q1 2026), $5.3 million (Q4 2025), and -$1.2 million (Q3 2025).